Terra Alpha Investments LLC Invests $1.22 Million in Stryker Corporation $SYK

Terra Alpha Investments LLC purchased a new stake in shares of Stryker Corporation (NYSE:SYK) during the 3rd quarter, Holdings Channel reports. The fund purchased 3,290 shares of the medical technology company’s stock, valued at approximately $1,216,000. Stryker makes up 1.2% of Terra Alpha Investments LLC’s holdings, making the stock its 29th biggest position.

A number of other hedge funds have also bought and sold shares of the company. Mid American Wealth Advisory Group Inc. bought a new position in Stryker during the 2nd quarter valued at about $26,000. Clayton Financial Group LLC bought a new stake in Stryker in the third quarter worth about $26,000. Elevation Point Wealth Partners LLC purchased a new position in shares of Stryker during the second quarter valued at approximately $28,000. Sachetta LLC grew its stake in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after buying an additional 27 shares during the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Stryker in the second quarter worth approximately $29,000. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the transaction, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at approximately $954,600,714.24. The trade was a 9.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 522,118 shares of company stock worth $185,381,932 over the last 90 days. Company insiders own 5.90% of the company’s stock.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Q4 results beat estimates — adjusted EPS $4.47 vs. $4.40 consensus and revenue of $7.17B (organic growth ~11%), with management citing strong Mako adoption as a growth driver. SYK Stock Gains as Q4 Earnings & Sales Beat on Strong Mako Adoption
• Positive Sentiment: Company raised its full‑year profit forecast and reported record revenue (>$25B FY2025) with adjusted operating margin expansion — supports upside to earnings expectations. Stryker raises annual profit forecast on strong sales for medical devices
• Positive Sentiment: Analysts are raising targets and reiterating buy ratings — Needham bumped its price target to $454 and reiterated Buy, reinforcing broker support after the print. SYK: Stryker price target raised by Needham Stryker: Sustained Double‑Digit Growth and Operating Leverage Support Buy Rating
• Neutral Sentiment: 2026 guidance: management expects 8.0%–9.5% organic sales growth and adjusted EPS $14.90–$15.10 (roughly in line with street consensus); guidance shows continued growth but is narrowly ranged. Stryker projects 8%–9.5% organic sales growth for 2026
• Neutral Sentiment: Operating performance detail — adjusted operating margin widened ~100 bps to 30.2% in Q4 and management emphasizes margin expansion and new product launches as 2026 drivers. Stryker reports 2025 operating results and 2026 outlook
• Negative Sentiment: Headwinds and risks flagged — analysts and the company note possible 2026 tariff pressures, regulatory and macro risks that could constrain upside; keep an eye on cost/price dynamics and geopolitics. Stryker: Sustained Double‑Digit Growth and Operating Leverage Support Buy Rating
• Negative Sentiment: Insider selling activity flagged in some data summaries — notable executive/insider sales were reported which some investors monitor as a negative signal (context and timing matter). Stryker Reports Strong Q4 and Full‑Year 2025 Results (Quiver summary)

Stryker Stock Performance

SYK stock opened at $369.39 on Friday. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $404.87. The business has a 50-day moving average price of $359.40 and a 200 day moving average price of $371.66. The company has a market capitalization of $141.26 billion, a P/E ratio of 43.97, a PEG ratio of 2.27 and a beta of 0.89. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.85 and a quick ratio of 1.13.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts’ consensus estimates of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.73%. The business had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter last year, the firm posted $4.01 EPS. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 30th. Investors of record on Wednesday, December 31st were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. This is a positive change from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend was Wednesday, December 31st. Stryker’s payout ratio is presently 46.25%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on SYK shares. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price objective for the company in a report on Tuesday, January 6th. Wall Street Zen downgraded Stryker from a “buy” rating to a “hold” rating in a research report on Saturday. UBS Group set a $408.00 price target on shares of Stryker in a report on Monday, October 13th. Barclays lifted their price objective on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Finally, Evercore ISI set a $390.00 price objective on shares of Stryker in a research report on Monday, January 5th. Twelve equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $426.95.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.